{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-24-000018","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.694246+00:00","generated_at":"2026-06-02T22:13:20.847847+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Krystal Biotech Q1 2024 net income $0.9M; VYJUVEK revenue $45.3M; cash $622M","bullets":["Net income $0.9M ($0.03 EPS) vs net loss $45.3M ($1.76 loss) in Q1 2023.","VYJUVEK net product revenue $45.3M, gross margin 95%, patient compliance 91%.","Cash $622.3M; FY 2024 Non-GAAP R&D+SG&A guidance $150M-$175M.","Pipeline: KB408 AATD first patient; KB407 CF Cohort 2 complete; inhaled KB707 first patient; intratumoral KB707 Cohort 3 enrolled.","Regulatory: European MAA decision and GMP certification expected 2H 2024; Japan NDA filing target 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-24-000018","json":"https://secwatch.observer/filing/0001711279-24-000018.json","markdown":"https://secwatch.observer/filing/0001711279-24-000018.md","text":"https://secwatch.observer/filing/0001711279-24-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127924000018/0001711279-24-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127924000018/krys-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:13:20.847847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7ccffa5710ddcf9c63b7f9875a94a66bf67f4634","claim":"Krystal Biotech, Inc. reported the first quarter ending March 31, 2024 results: revenue $45.3 million.","evidence_excerpt":"The Company recorded $45.3 million in VYJUVEK net product revenue for the first quarter of 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127924000018/0001711279-24-000018-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ending March 31, 2024"},{"label":"Revenue","value":"$45.3 million"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}